Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.65 |
| ▸ | JAK1 | P23458 | 11/20 | 0.65 |
| ▸ | JAK3 | P52333 | 4/20 | 0.65 |
| ▸ | TYK2 | P29597 | 3/20 | 0.65 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.54 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15654465 | 0.84 | JAK2 (0.65) | JAK2JAK1JAK3TYK2NUDT1 | |
| SCHEMBL15654785 | 0.82 | JAK2 (0.59) | JAK2JAK1JAK3TYK2NUDT1 | |
| SCHEMBL22511942 | 0.81 | JAK2 (0.71) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL15652948 | 0.81 | JAK2 (0.68) | JAK2JAK1JAK3TYK2NUDT1 | |
| SCHEMBL15654412 | 0.81 | JAK1 (0.68) | JAK2JAK1JAK3TYK2NUDT1 | |
| SCHEMBL3777612 | 0.81 | JAK1 (0.66) | JAK2JAK1JAK3TYK2NUDT1 | |
| SCHEMBL15654398 | 0.81 | JAK2 (0.68) | JAK2JAK1JAK3TYK2NUDT1 | |
| SCHEMBL15654621 | 0.79 | JAK1 (0.57) | JAK2JAK1JAK3TYK2NUDT1 | |
| SCHEMBL15654966 | 0.79 | JAK2 (0.70) | JAK2JAK1JAK3TYK2NUDT1 | |
| Solcitinib SCHEMBL2240393 | 0.79 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2792677-B1 | Novel compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2017-04-26 | — | — | EP | disclosed |
| US-9505754-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2016-11-29 | — | — | US | disclosed |
| US-9415037-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2016-08-16 | — | — | US | disclosed |
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| US-20150031671-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GILEAD SCIENCES, INC. | 2015-01-29 | — | — | US | disclosed |
| EP-2792677-A1 | Novel compound useful for the treatment of degenerative and inflammatory diseases | Galapagos N.V. (BE) | 2014-10-22 | — | — | EP | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2445912-B1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| US-8796457-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-08-05 | — | — | US | disclosed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| EP-2445912-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2012-05-02 | — | — | EP | disclosed |
| US-20100331359-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GILEAD SCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010149771-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | JAK2 242/4885JAK1 100/4885JAK3 211/4885 |
| US-20100331359-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, BMP6, TRAF6 | JAK2 401/4885JAK1 274/4885JAK3 552/4885 |
| US-20150031671-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, BMP6, TRAF6 | JAK2 401/4885JAK1 274/4885JAK3 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.